National Academies Press: OpenBook
« Previous: Appendix E.2: International Science and Technology Center
Suggested Citation:"Appendix E.3: Skolkovo Foundation and Innovation Center." National Research Council. 2013. The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions. Washington, DC: The National Academies Press. doi: 10.17226/18277.
×

Appendix E.3

Skolkovo Foundation and Innovation Center

The Skolkovo Foundation is a Russian nonprofit organization established in 2010 with the task of creating a science and technology innovation center in the Moscow suburb of Skolkovo. The strategic goal of the Skolkovo Innovation Center is to concentrate international and domestic capital within a hub that will nurture and stimulate the development and commercialization of advanced technologies and house up to 1,000 start-up companies.

The initiative has been financed primarily by the Russian government, which decided to allocate more than $3.2 billion to the activity from 2011 to 2015. The funds are to come largely from the state Bank for Development and Foreign Economic Affairs, Vnesheconombank, with the state’s initial commitment fixed at 88.5 billion rubles (ruble-dollar exchange rate in May 2012 was 30-1). The center’s budget in 2010 was 3.9 billion rubles. The allocation was 22 billion rubles for 2012 and 17.3 billion rubles for 2013.

The project includes 40 innovation business incubators and technoparks and 80 venture funds—some of which are currently operating in various areas of Russia. In April 2012, there were 1,950 employees at Russian research centers supporting Skolkovo, which are also distributed throughout the country. This number is scheduled to grow to 2,500 by the end of 2012. At this initial stage, there is no requirement for matching contributions for receiving financing from the foundation, but the planned goal is to have 3-1 matching contributions when production activities are initiated. The number of companies that are involved is expected to grow from 20 in 2012 to 30–50 by 2015–2016.

Almost 300 companies/participants have expressed interest in the project. About 20 percent of applications by companies for financial support have been approved. Companies and other organizations with activities under Skolkovo’s

Suggested Citation:"Appendix E.3: Skolkovo Foundation and Innovation Center." National Research Council. 2013. The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions. Washington, DC: The National Academies Press. doi: 10.17226/18277.
×

purview operate by laws that facilitate participation of international companies and encourage innovation. These laws provide tax breaks and administrative benefits, such as onsite customs facilitation and work permit issuance to overcome bureaucratic delays.

Biomedicine is one of the main sectors of interest. Eleven of 30 grant applications for biomedical start-ups had been approved by April 2012. A total of $76 million had been invested, with each grant for $2–5 million over 3–5 years. The strategic goal of the biomedicine cluster is to create an ecosystem for biomedical innovations that consists of more than 90 companies.

The biomedicine cluster focuses on four main fields: (1) clinical medicine and health care, (2) medical-biological and biological sciences, (3) bioinformatics, and (4) industrial biotechnologies (including purification methods and industrial technologies for the production of medical preparations). Plans call for a preclinical medicine testing center for cluster residents that should start operating in 2013. According to this plan, the companies will not have to transfer money from abroad to pay for preclinical testing of medicines.

The following U.S. companies have shown interest in activities of the cluster: Johnson and Johnson, Agenus, Pfizer, AstraZeneca, and Dow Chemical. ChemRar Ventures has entered into licensing and research agreements with Skolkovo Foundation, Johnson and Johnson, and Pfizer.

SOURCE: Information provided by Skolkovo Foundation, April 2012.

Suggested Citation:"Appendix E.3: Skolkovo Foundation and Innovation Center." National Research Council. 2013. The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions. Washington, DC: The National Academies Press. doi: 10.17226/18277.
×
Page 217
Suggested Citation:"Appendix E.3: Skolkovo Foundation and Innovation Center." National Research Council. 2013. The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions. Washington, DC: The National Academies Press. doi: 10.17226/18277.
×
Page 218
Next: Appendix E.4: Skolkovo Institute of Science and Technology »
The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions Get This Book
×
Buy Paperback | $54.00 Buy Ebook | $43.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

In the fall of 2010, the U.S. National Academies (consisting of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine) and the Russian Academy of Sciences (in cooperation with the Russian Academy of Medical Sciences and the Russian Academy of Agricultural Sciences) initiated a joint study of U.S.-Russian bilateral engagement in the biological sciences and biotechnology (hereinafter collectively referred to as bioengagement). The U.S. Department of State and the Russian Academy of Sciences provided support for the study. The academies established a joint committee of 12 leading scientists from the two countries to assess bioengagement activities since 1996 and to provide recommendations as to collaborative efforts in the near future. The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions summarizes the principal conclusions and recommendations of the study.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!